#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Months after capmatinib — the MET inhibitor designed to cross the blood-brain barrier discovered by Incyte and licensed by Novartis — secured the FDA’s priority review in patients with a form of lung cancer, the Swiss drugmaker has reported encouraging, albeit early, data in patients whose cancer had spread to the brain.
Data from 13 patients with metastatic MET exon 14 skipping non-small cell lung cancer with brain metastases, were unveiled at the virtually-held American Association for Cancer Research conference on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.